On the 30 of December 2025 the Annual General Shareholders Meeting of VILNIAUS BALDAI AB adopted the following resolutions: Agenda item #1: Consolidated Management Report. The Company‘s consolidated management report for the FY 2025 ended 31 August 2025 was presented. Agenda item #2: Company‘s Auditor's Report. The report of the audit company Grant Thornton Baltic UAB on the consolidated and the Company’s financial statements for the FY 2025, ended on 31 August 2025, was presented. Agenda item #3: Approva ...

Core Points - Sasol held its annual general meeting on November 14, 2025, where all resolutions were passed by the requisite majority of voting rights exercised [1] - The audited annual financial statements for the financial year ended June 30, 2025, were presented [1] Remuneration Policy - Non-binding advisory resolution number 1 endorsed the Company's remuneration policy with 93.93% votes in favor [2] - Non-binding advisory resolution number 2 endorsed the implementation report of the Company's remuneration policy with 97.43% votes in favor [2] Climate Change Strategy - Non-binding advisory resolution number 3 endorsed Sasol's climate change mitigation and adaptation strategy with 85.30% votes in favor [3] Director Elections - Mr. S Baloyi was re-elected as a director with 99.84% votes in favor [3] - Mr. M J Cuambe was re-elected as a director with 99.54% votes in favor [3] - Ms. M B N Dube was re-elected as a director with 97.74% votes in favor [3] - Dr. M Flöel was re-elected as a director with 99.50% votes in favor [3] Audit Committee Appointments - KPMG Inc. was appointed as the independent auditor with 99.90% votes in favor [4] - Several members were elected to the Audit Committee with high approval rates, including Mr. D G P Eyton (99.20%), Ms. K C Harper (99.55%), and Ms. G M B Kennealy (99.19%) [4][5] Safety, Social and Ethics Committee Appointments - Members elected to the Safety, Social and Ethics Committee included Mr. S Baloyi (99.42%), Ms. M B N Dube (98.07%), and Dr. M Flöel (99.30%) [5] Special Resolutions - Special resolution number 1 to approve remuneration for non-executive directors received 98.07% votes in favor [5] - Special resolution number 2 to authorize the Board for general share repurchase received 77.63% votes in favor [5]

Core Points - Pharma Equity Group A/S held its Annual General Meeting on April 16, 2025, where various proposals were discussed and adopted [1][6] Group 1: Board of Directors' Report - The former CEO, Thomas Kaas Selsø, presented the Board's report on the Company's activities over the past year, addressing shareholder questions regarding the Market Maker agreement with Danske Bank and the potential delisting from Nasdaq Copenhagen [3][4] - Shareholders expressed concerns about the declining share price, attributing it to large shareholders selling their shares, while also acknowledging the Company's successful financing in 2024 and positive research results [4][5] Group 2: Financial Proposals - The audited 2023 annual report was presented, and the discharge of the Board and Executive Management was proposed, with no objections raised from shareholders [8][11] - The expected revenue for the current financial year was projected at DKK 11 million, based on valuations prepared by Baker Tilly and reviewed by Danske Bank [9] - Outstanding convertible loans were confirmed to total approximately DKK 13 million [10] Group 3: Remuneration and Board Elections - The remuneration for the Board of Directors for the 2025 financial year was proposed, with the Chairman receiving DKK 350,000 and Board members receiving DKK 150,000 [14] - All current Board members were re-elected, and two new members, Troels Peter Troelsen and Charlotte Pahl, were elected [16][17] - BDO Statsautoriseret Revisionsaktieselskab was re-elected as the Company's auditor [18] Group 4: Proposals and Authorizations - Three proposals from the Board were discussed, requiring different majorities for adoption, and all were approved without objections [19][20] - The chairman was authorized to file the adopted resolutions with the Danish Business Authority [21] Group 5: Company Overview - Pharma Equity Group A/S is dedicated to advancing the medical projects of its subsidiary, Reponex Pharmaceuticals A/S, with a focus on healthcare and innovative medical solutions [23][24]